$IONS

$42.86▲ -2.4% YTD

8 SEC 13D/G filings tracked · Last updated Oct 23, 2026

Filing History

IONS ▼ -2.4% - Ionis Pharmaceuticals, Inc.

CP $42.86▲ -2.4%Oct 23, 2026 · ThinkSabio Blog

$IONS Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)…

News

IONS ▲ +1.6% - Ionis Pharmaceuticals, Inc.

CP $44.96▲ +1.6%Oct 22, 2026 · ThinkSabio Blog

$IONS u/g Outperform @ BMO pt $66…

News

IONS ▼ -1.3% - Ionis Pharmaceuticals, Inc.

CP $43.56▲ -1.3%Oct 16, 2026 · ThinkSabio Blog

$IONS TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)…

News

IONS ▲ +3.6% - Ionis Pharmaceuticals, Inc.

CP $47.38▲ +3.6%Sep 23, 2026 · ThinkSabio Blog

$IONS Ionis / Roche: Sefaxersen Hits Phase 3 Primary Endpoint in IgA Nephropathy ? • Interim Phase 3 showed statistically significant, clinically mean…

News

IONS ▲ +3.7% - Ionis Pharmaceuticals, Inc.

CP $46.55▲ +3.7%Sep 22, 2026 · ThinkSabio Blog

$IONS Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential dise…

News

IONS ▲ +3.3% - Ionis Pharmaceuticals, Inc.

CP $46.39▲ +3.3%Sep 22, 2026 · ThinkSabio Blog

$IONS Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential dise…

News

IONS ▼ -6.3% - Ionis Pharmaceuticals, Inc.

CP $54.50▲ -6.3%Sep 4, 2026 · ThinkSabio Blog

$IONS Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascu…

News

IONS ▼ -5.1% - Ionis Pharmaceuticals, Inc.

CP $58.17▲ -5.1%Sep 3, 2026 · ThinkSabio Blog

$IONS small volume…